EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study

Panagiota Xanthouli iD, Paul Uesbeck, Hanns-Martin Lorenz, Norbert Blank, Christina A Eichstaedt iD, Satenik Harutyunova, Benjamin Egenlauf, Jerry G Coghlan, Christopher P Denton, Ekkehard Grünig iD, Nicola Benjamin iD

Arthritis Research & Therapy · 18.07.2024 · 26 (1)

DOI: 10.1186/s13075-024-03363-0 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Arthritis Research & Therapy, online erschienen am 18.07.2024. Verfasst von Panagiota Xanthouli und 10 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg GmbH at Heidelberg University Hospital, Röntgenstraße 1, 69126, Heidelberg, Germany. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Phenylpropionates, Pyridazines, Antihypertensive Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Heidelberg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In the EDITA trial, patients with systemic sclerosis (SSc) and mild pulmonary vascular disease (PVD) treated with ambrisentan had a significant decline of pulmonary vascular resistance (PVR) but not of mean pulmonary arterial pressure (mPAP) vs. placebo after six months. The EDITA-ON study aimed to assess long-term effects of open label therapy with ambrisentan vs. no pulmonary arterial hypertension (PAH) therapy.

Methods

Patients who participated in the EDITA study and received regular follow-up were included in EDITA-ON. Clinical, echocardiographic, laboratory, exercise and hemodynamic parameters during follow-up were analysed. The primary endpoint was to assess whether continued treatment with ambrisentan vs. no treatment prevented the development of PAH according to the new definition.

Results

Of 38 SSc patients included in the EDITA study four were lost to follow-up. Of the 34 remaining patients (age 55 ± 11 years, 82.1% female subjects), 19 received ambrisentan after termination of the blinded phase, 15 received no PAH medication. The mean follow-up time was 2.59 ± 1.47 years, during which 29 patients underwent right heart catheterization. There was a significant improvement of mPAP in catheterised patients receiving ambrisentan vs. no PAH treatment (-1.53 ± 2.53 vs. 1.91 ± 2.98 mmHg, p = 0.003). In patients without PAH treatment 6/12 patients had PAH vs. 1/17 of patients receiving ambrisentan ( p < 0.0001).

Conclusion

In SSc patients with early PVD, the development of PAH and/or deterioration was less frequent among patients receiving ambrisentan, indicating that early treatment and close follow-up could be beneficial in this high-risk group. Future trials in this field are needed to confirm these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Scleroderma, SystemicPhenylpropionatesPyridazinesAntihypertensive AgentsHumansFemaleMaleMiddle AgedFollow-Up StudiesAdultAgedTreatment OutcomePulmonary Arterial HypertensionHypertension, Pulmonary

Stichwörter der Autor:innen

AmbrisentanEarly treatmentPulmonary vascular diseaseSystemic sclerosis

Substanzen

ambrisentanPhenylpropionatesPyridazinesAntihypertensive Agents

Autor:innen und Institutionen

  • Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg GmbH at Heidelberg University Hospital, Röntgenstraße 1, 69126, Heidelberg, Germany.
  • Translational Lung Research Centre Heidelberg (TLRC), German Centre for Lung Research (DZL), Heidelberg, Germany.
  • Department of Pneumology and Critical Care Medicine, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Heidelberg, Germany.
  • Department of Internal Medicine V: Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
  • Cardiology Department, Royal Free Hospital, London, UK.
  • Centre of Rheumatology, Royal Free Hospital, London, UK.

ORCID-Profile: Panagiota Xanthouli, Christina A Eichstaedt, Ekkehard Grünig, Nicola Benjamin

Förderung

  • Universitätsklinikum Heidelberg

Zitieren

APA

Xanthouli, P., Uesbeck, P., Lorenz, H. M., Blank, N., Eichstaedt, C. A., Harutyunova, S., Egenlauf, B., Coghlan, J. G., Denton, C. P., Grünig, E., & Benjamin, N. (2024). Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study. Arthritis Research & Therapy, 26(1). https://doi.org/10.1186/s13075-024-03363-0

Vancouver

Xanthouli P, Uesbeck P, Lorenz HM, Blank N, Eichstaedt CA, Harutyunova S, et al. Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study. Arthritis Research & Therapy. 2024;26(1). doi:10.1186/s13075-024-03363-0

BibTeX
@article{Xanthouli2024,
  author = {Xanthouli, Panagiota and Uesbeck, Paul and Lorenz, Hanns-Martin and Blank, Norbert and Eichstaedt, Christina A and Harutyunova, Satenik and Egenlauf, Benjamin and Coghlan, Jerry G and Denton, Christopher P and Grünig, Ekkehard and Benjamin, Nicola},
  title = {Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study},
  journal = {Arthritis Research & Therapy},
  year = {2024},
  volume = {26},
  number = {1},
  doi = {10.1186/s13075-024-03363-0}
}
Kostenlos starten →